


PRODUCT INFORMATION



Des-4-fluorobenzyl Mosapride

Item No. 22157

CAS Registry No.: 152013-26-8
Formal Name: 4-amino-5-chloro-2-ethoxy-N-(2-morpholinylmethyl)-benzamide
Synonym: Des-*p*-fluorobenzyl Mosapride
MF: C₁₄H₂₀ClN₃O₃
FW: 313.8
Purity: ≥90%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Des-4-fluorobenzyl Mosapride is supplied as a solid. A stock solution may be made by dissolving the des-4-fluorobenzyl mosapride in the solvent of choice. Des-4-fluorobenzyl Mosapride is slightly soluble in chloroform and methanol (warmed).

Description

Des-4-fluorobenzyl Mosapride is the primary metabolite of mosapride. Mosapride is a gastroprokinetic agent that enhances upper GI motility by activating serotonin receptor 4 (5-HT₄; EC₅₀ = 74.2 nM, in guinea pig ileal longitudinal muscle myenteric plexus).^{1,2} Mosapride increases canine, equine, and guinea pig colonic motility *in vivo*.^{3,4} Formulations containing mosapride are used in human and veterinary medicine to prevent post-surgical- and Parkinson's-induced constipation.^{3,5}

References

1. Mine, Y., Yoshikawa, T., Oku, S., *et al.* Comparison of effect of mosapride citrate and existing 5-HT₄ receptor agonists on gastrointestinal motility *in vivo* and *in vitro*. *J. Pharmacol. Exp. Ther.* **283**(3), 1000-1008 (1997).
2. Yoshida, N. and Ito, T. Mosapride citrate (AS-4370), a new gastroprokinetic agent, is a partial 5-HT₄ receptor agonist in the gut. *Neurogastroenterol. Motil.* **6**(3), 197-204 (1994).
3. Yoshida, N., Ito, T., Karasawa, T., *et al.* AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. *J. Pharmacol. Exp. Ther.* **257**(2), 781-787 (1991).
4. Okamura, K., Sasaki, N., Yamada, N., *et al.* Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility. *Res. Vet. Sci.* **86**(2), 302-308 (2009).
5. Liu, Z., Sakakibara, R., Odaka, T., *et al.* Mosapride citrate, a novel 5-HT₄ agonist and partial 5-HT₃ antagonist, ameliorates constipation in parkinsonian patients. *Mov. Disord.* **20**(6), 680-686 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/14/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM